The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Clinical Studies Of Novel Antiviral Therapies In Advanced Chronic Hepatitis B Virus Infection.
Funder
National Health and Medical Research Council
Funding Amount
$64,631.00
Summary
There is an urgent need to develop therapies for treating and preventing Hepatitis B antiviral resistance, particularly in patients with advanced liver disease. Investigator-initiated clinical studies will be performed to examine a) the most effective therapy for preventing antiviral resistance and Hepatitis B recurrence following liver transplantation and b) the effect of a novel Hepatitis B antiviral, tenofovir, on multi-resistant chronic Hepetatis B infection.
Next Generation Sequencing Of Hepatitis C Virus To Detect Drug Resistance Mutations
Funder
National Health and Medical Research Council
Funding Amount
$39,497.00
Summary
Hepatitis C is the leading cause of liver cancer and liver failure requiring transplantation in Australia. New antiviral drugs set to revolutionise hepatitis C treatment by substantially improving cure rates could be challenged by the development of resistance mutations, which would make these drugs less effective. We aim to develop a practical test to be used routinely to guide clinicians in choosing appropriate anti-viral drugs for their patients.